U.S. Patent Office Issues Guidance to Examiners on Supreme Court's Myriad Decision

14 June 2013 Cleantech & Nano Publication

Today the USPTO issued guidance (PTO_Myriad_Guidelines) to Examiners on how to apply the Myriad Supreme Court decision to applications under examination. The guidance states that claims drawn “solely to naturally occurring nucleotide sequences or fragments” should be rejected for lack of eligibility under 35 U.S.C. 101. The guidance indicates that this is only a preliminary guidance memo, and that a more detailed guidance document will be issued to examiners in the future.

As noted in our earlier post, the Myriad decision has left plenty of room for nanotech patents, despite the finding that naturally occurring genes are unpatentable. The USPTO’s preliminary guidance appears in line with the decision and does not alter that general view.

Related Services

Insights

Foley Weekly Automotive Report
03 August 2021
Dashboard Insights
Podcast Episode 57: Kristel Schorr, Partner
03 August 2021
Foley Career Perspectives
New Facebook Policy Requires Certification and Pre-Approval for Telemedicine Company Advertisements
03 August 2021
Health Care Law Today
Act Now: Employer Obligations Under New York HERO Act
02 August 2021
Labor & Employment Law Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream